Claude
The web reveals a company in the middle of the most consequential ownership transition in its history. The Burman family (Dabur promoters) completed a hostile-turned-successful takeover in February 2025, ousted long-time chairperson Dr. Rashmi Saluja amid insider trading allegations and a ₹68.86 crore compensation controversy, and on 14 February 2026 announced a strategic demerger to split insurance (Care Health) from financial services (Religare Finvest). The single most important finding: Care Health Insurance is valued at approximately ₹16,000 crore and has tripled its gross premiums to ₹8,135 crore with a 22% SAHI market share – yet the parent REL trades at only ~₹7,400 crore market cap, suggesting the market assigns negative value to the NBFC, broking, and holding company layers. The demerger, if executed, could unlock this gap – but NCLT approval and RFL listing are not expected until Q1 FY28.
**Burman takeover completed but governance transition still unfolding.** The Burman family acquired a 25.16% controlling stake via a ₹2,116 crore open offer at ₹235/share (closed Feb 13, 2025), but only 0.07% of public shares were tendered -- a strikingly tepid response. Three Burman family members (Anand Chand Burman, Mohit Burman, Aditya Chand Burman) and Samco Group CEO Jimeet Modi were inducted to the board in February 2026. A concrete consolidation plan must be submitted within 90 days, with full consolidation by March 31, 2026. Sources: [Livemint](https://www.livemint.com/market/stock-market-news/burman-family-acquires-controlling-stake-in-religa), [Business Standard](https://www.business-standard.com/companies/news/religare-board-appoints-burman-family-members-12511)
**Strategic demerger announced on Feb 14, 2026 to separate insurance from financial services.** REL will retain Care Health Insurance; lending, broking, and investment activities transfer to Religare Finvest Ltd (RFL). RFL shares to be issued 1:1 to REL shareholders. RFL listing targeted for Q1 FY28 on BSE and NSE. The demerger requires NCLT, shareholder, creditor, and regulatory approvals. Sources: [Moneycontrol](https://www.moneycontrol.com/news/business/banks/religare-enterprises-likely-to-announce-demerger-an), [Whalesbook](https://www.whalesbook.com/news/English/bankingfinance/Religare-Enterprises-Plans-Demerger-Amid-Valu)
**Dr. Rashmi Saluja ousted amid insider trading and compensation controversy.** Saluja earned ₹68.86 crore in FY24 (7th highest-paid CEO in India, 3rd in BFSI), including ₹14.12 crore excluding ESOPs. She sold Religare shares after meeting a Burman family representative at The Oberoi on Sept 20, 2023, just before the open offer announcement, potentially violating SEBI insider trading rules. She sued Religare in Delhi High Court to block her removal at the Feb 2025 AGM, but ultimately lost the battle. Sources: [Livemint](https://www.livemint.com/news/india/mint-explainer-is-dr-rashmi-salujas-battle-against-the-burmans-w), [NDTV Profit](https://www.ndtvprofit.com/exclusive/rashmi-saluja-faces-calls-for-removal-during-care-health-insura)
**RBI lifted Corrective Action Plan on Religare Finvest on July 23, 2025.** This is a critical positive milestone. RFL had cumulative losses of ₹2,270 crore up to March 2022 and was placed under CAP due to large-scale fund misappropriation. RFL completed a one-time settlement with 16 lenders in March 2023, repaying over ₹9,000 crore. The CAP withdrawal now allows RFL to resume normal lending operations. Source: [Moneycontrol](https://www.moneycontrol.com/news/business/markets/religare-enterprises-rbi-lifts-corrective-action-)
**Care Health Insurance has tripled premiums and gained significant market share.** Gross premiums grew from ~₹2,700 crore in FY21 to ₹8,135 crore in FY25, boosting its SAHI market share from 15% to 22%. The incurred claim ratio for FY26 is 58.32% per IRDAI. Unlisted shares trade at ~₹120/share. Care Health is valued at approximately ₹16,000 crore, and Kedaara Capital (15.86% stake) can facilitate an IPO by 2026 per the Articles of Association. Sources: [Moneycontrol](https://www.moneycontrol.com/banking/standalone-health-insurance-market-nearly-doubles-even-as-star-), [Policyx](https://www.policyx.com/health-insurance/religare-health-insurance/incurred-claim-ratio/)
**IRDAI show-cause notice and ₹1 crore penalty on Care Health Insurance.** IRDAI conducted a thematic onsite inspection of Care Health (Feb 10-14, 2025) and issued a show-cause notice alleging breaches of multiple 2024 master circulars on operations, policyholder protection, health insurance business, product rules, and actuarial functions. A separate ₹1 crore penalty was issued on Dec 15, 2025, for violations discovered during a 2021 inspection. Sources: [InvestyWise](https://www.investywise.com/religare-enterprises-subsidiary-receives-show-cause-notice/), [ScanX Trade](https://scanx.trade/stock-market-news/stocks/religare-enterprises-subsidiary-care-health-insurance-p)
**Historical fund diversion of $400 million by erstwhile promoters (Singh brothers).** The Enforcement Directorate (ED) established diversion of $400 million to a subsidiary in Mauritius and then to a Jersey-based entity. ED raided 9 premises in January 2024. Lenders had tagged REL as fraud, which prevented RFL debt restructuring until management change occurred. NFRA penalized auditor Neeraj Bansal ₹5 lakh and barred him for 5 years for lapses in auditing RFL for 2017-18. Sources: [Business Standard](https://www.business-standard.com/article/companies/ed-unearths-400-million-fund-diversion-at-religa), [NFRA Report](https://www.livemint.com)
**RFL debt restructuring entering final stage but execution risk remains.** SBI has given preliminary approval for a revised debt restructuring plan for RFL. RFL's expenditure exceeded ₹639 crore while income stood at just ₹275 crore in a recent year. REL settled with SEBI for ₹10.5 crore related to financial mismanagement and fund diversion allegations. Sources: [Business Standard](https://www.business-standard.com/article/companies/religare-finvest-s-revised-debt-restructuring-pl), [Business Standard Settlement](https://www.business-standard.com/article/companies/religare-enterprises-religare-finvest-settle-seb)
**Stock rated "Strong Sell" by MarketsMojo as of Feb 2026.** Negative profitability indicators, low promoter holding, and bearish technical signals. REL shares fell 9% post-demerger announcement (from Feb 14, 2026). One analyst target price at ₹273, with DCF intrinsic value estimate of ₹254. Market cap approximately ₹7,400 crore. Sources: [MarketsMojo](https://www.marketsmojo.com/news/stock-recommendation/religare-enterprises-ltd-i), [Alpha Spread](https://www.alphaspread.com)
Dr. Rashmi Saluja was the central figure in the governance battle. Appointed Independent Director in December 2018 and later elevated to Executive Chairperson, her ₹68.86 crore FY24 compensation (making her the 7th highest-paid CEO in India) at a company with negative profitability was a major red flag. The revelation that she sold Religare shares after a meeting with a Burman representative on September 20, 2023, before the open offer was publicly announced, exposed potential insider trading. She filed a lawsuit against Religare in Delhi High Court seeking to block the AGM vote on her reappointment, in what observers called one of the first such corporate lawsuits. Ultimately, 97%+ of shareholders voted against her reappointment.
The Burman Family executed a textbook hostile takeover over 18 months, starting with initial stake acquisitions in 2018 and culminating in the February 2025 open offer. Despite only 0.07% of public shareholders tendering, the family had already secured sufficient ownership. RBI imposed a condition that a concrete consolidation plan be submitted within 90 days and completed by March 31, 2026. The family is expected to invest up to ₹5,000 crore across Religare subsidiaries.
The Indian health insurance market is projected to grow at 8-17% CAGR through 2031, with standalone health insurers (SAHI) expected to outpace general insurers at a 17.32% CAGR. Within the SAHI segment, Care Health has been a standout performer, tripling its gross premium base from ₹2,700 crore in FY21 to ₹8,135 crore in FY25, while Star Health's dominance has halved from ~48% to ~38% market share. Niva Bupa has also gained share aggressively. Digital and online distribution channels are projected to post a 22.34% CAGR through 2031, a structural tailwind.
Key competitive dynamics relevant to Religare: (1) Care Health's 22% market share makes it the second-largest SAHI player after Star Health, (2) the incurred claim ratio of 58.32% in FY26 is healthy and suggests underwriting discipline, (3) the insurance sector is forecast for 6.9% annual premium growth through 2030, and (4) Kedaara Capital's ability to facilitate a Care Health IPO by 2026 per the Articles of Association could be a near-term catalyst if the Burmans choose that route instead of the demerger.
All figures in INR unless stated otherwise. Data sourced from Brave Search results and full-page web content as of early April 2026.